Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Notes underwriting agrmnt
Adamis Pharmaceuticals Corp (ADMP) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
08/21/2023 8-K Quarterly results
Docs: "Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update"
08/03/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "PLACEMENT AGENCY AGREEMENT",
"Opinion of Weintraub Tobin Chediak Coleman Grodin, law corporation",
"SECURITIES PURCHASE AGREEMENT",
"Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering"
07/31/2023 8-K Quarterly results
07/28/2023 8-K Quarterly results
07/24/2023 8-K Quarterly results
07/24/2023 8-K Quarterly results
05/26/2023 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ...
Docs: "Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock",
"Letter dated May 24, 2023, between the Company and David J. Marguglio",
"Offer letter dated May 24, 2023, between the Company and Ebrahim Versi, M.D., Ph.D",
"DMK 2016 Stock Plan",
"SAN DIEGO, May 25, 2023 – Adamis Pharmaceuticals Corporation"
05/16/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
05/15/2023 8-K Quarterly results
Docs: "Q1 2023 Corporate Highlights"
05/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
04/17/2023 8-K Quarterly results
03/17/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "TRANSCRIPT OF CONFERENCE CALL",
"TRANSCRIPT OF VIDEO PRESENTATION",
"Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update"
03/16/2023 8-K Quarterly results
Docs: "Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update"
03/14/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Form of Common Stock Purchase Warrant",
"Form of Prefunded Common Stock Purchase Warrant",
"Opinion of Latham & Watkins, LLP",
"Form of Securities Purchase Agreement",
"Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering SAN DIEGO, March 14, 2023 -- Adamis Pharmaceuticals Corporation , a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced it has entered into a securities purchase agreement with a single, healthcare-focused institutional investor for the purchase and sale of 16,500,000 shares of its common stock and pre-funded warrants to purchase up to 7,500,000 shares of common stock, together with warrants to purchase up to 48,000,000 shares of common stock, at a combined purchase price of $0.125 per share and accompanying warrants, pursuant to a registered direct..."
02/27/2023 8-K Acquisition/merger/asset purchase announced
Docs: "AGREEMENT AND PLAN OF REORGANIZATION",
"FORM OF SUPPORT AGREEMENT",
"SAN DIEGO and SOMERVILLE, NJ February 27, 2023"
02/23/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...
12/30/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
10/04/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/04/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SAN DIEGO, October 3, 2022-- Adamis Pharmaceuticals Corporation , a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, announced today that following the recently announced halting of the Company’ s Phase 2/3 clinical trial examining the effects of Tempol in high risk subjects with early COVID-19 infection, it has initiated a process to explore a range of strategic and financing alternatives focused on maximizing stockholder value. Potential alternatives that may be explored or evaluated include a partnership or sale of one or both of the Company’ s commercial products SYMJEPI and ZIMHI, a merger, sale, or reverse merger of the Company, and/o..."
09/23/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "OPINION OF LATHAM & WATKINS, LLP"
09/21/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Interim data from the Phase 2/3 clinical trial of Tempol did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo"
09/12/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
08/17/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
08/01/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Interim DSMB review expected in late September SAN DIEGO, July 29, 2022 -- Adamis Pharmaceuticals Corporation today provided an update on the Company’ s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19. The next Data Safety Monitoring Board meeting to review interim data results has been scheduled for late September. The DSMB previously met to evaluate the clinical and safety data from interim analyses in March and June 2022, and both times recommended that the study continue without modification. The DSMB is comprised of infectious disease experts who independently review the unblinded trial data and make recommendations. The Company will not have access to unblinded trial data until the trial has concluded. At the September m..."
07/29/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "ISS Recommends Stockholders Support Key Proposals Pertaining to a Reverse Stock Split and New Equity Incentive Plan The Deadline for Stockholders to Vote is 11:59 p.m. PT on August 11, 2022"
07/06/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
05/26/2022 8-K Quarterly results
05/18/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy